Street View: Karyopharm's cancer drug trial results limit regulatory odds

Karyopharm Therapeutics

25/03/2026 11:49

** Karyopharm Therapeutics KPTI.O said on Tuesday its therapy led to significant reduction in spleen size in a late-stage study of patients with myelofibrosis, a rare blood cancer, meeting only one of its two main goals

** The drug combination failed to meet the study's second main goal of statistically significant symptom improvement

** At least two analysts lowered PT on the company

MIXED RESULTS DIM CHANCE OF APPROVAL

** Cantor Fitzgerald ("overweight") says the likelihood of FDA approval is minimal, given the regulatory precedent of placing significant importance on showing clear symptom improvement

** H.C. Wainwright ("buy," PT: $8) says missing the symptom goal weakens KPTI's path with regulators, noting other myelofibrosis drugs with similar results were not taken forward, though early survival data could still provide support

** RBC Capital Markets ("outperform," PT: $23) says "the data is clearly imperfect, but between spleen, survival, and hints of disease modification, we believe there is enough here to warrant regulatory discussions"

** Jefferies ("buy," PT: $14) says there is low chance of FDA approval, based on the current results, even though the early survival signal could still provide support

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))